ABSTRACT
OBJECTIVE@#To explore the expression pattern and clinical significance of Integral membrane protein 2A（ITM2A） in drug resistant patients with chronic myeloid leukemia (CML).@*METHODS@#The expression of ITM2A in CML was evaluated by qRT-PCR, Western blot and immunocytochemistry. In order to understand the possible biological effects of ITM2A, apoptosis, cell cycle and myeloid differentiation antigen expression of CML cells were detected by flow cytometry after over-expression of ITM2A. The nuderlying molecular mechanism of its biological effect was explored.@*RESULTS@#The expression of ITM2A in bone marrow of CML resistant patients was significantly lower than that of sensitive patients and healthy donors（P<0.05）. The CML resistant strain cell K562R was successfully constructed in vitro. The expression of ITM2A in the resistant strain was significantly lower than that in the sensitive strain(P<0.05). Overexpression of ITM2A in K562R cells increased the sensitivity of K562R cells to imatinib and blocked the cell cycle in G2 phase(P<0.05), but did not affect myeloid differentiation. Mechanistically, up-regulation of ITM2A reduced phosphorylation in ERK signaling (P<0.05).@*CONCLUSION@#The expression of ITM2A was low in patients with drug resistance of CML, and the low expression of ITM2A may be the key factor of imatinib resistance in CML.
Subject(s)
Humans , Antineoplastic Agents/pharmacology , Apoptosis , Drug Resistance, Neoplasm , Imatinib Mesylate/therapeutic use , K562 Cells , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Signal TransductionABSTRACT
This paper reports reaction of Bacillus lichendermis on the inhibitor vacations. The result Shows that, inhibition of the 500?g/mL of cephalosporin 1000?g/mL of penicillin, 500?g/mL of streptimycin, on the Bacillus Licheniformis,Whe the Phis 7.0. This provides a sicentific basis for using the preparation of Bacillus licheniformis.
ABSTRACT
Objective To develop a rapid and sensitive method for the determination of the percentage of blood chlormezanone by gas chromatograpy-mass spectrometry(GC/MS)for the clinical application on acute poisoning patients.Methods Chlormezanone in blood was extracted and separated with acetic ether.The acetic ether extractives from the blood were warmed with water at 80℃ and blown to dry with nitrogen gas.The dry extractives were then dissolved in 100?l of ethanol for GC/MS.To set up the linear equation for the determination of blood chlormezanone,draw the standard curve,calculate the extractive yield,detection limit and repeatability of chlormezanone.The GC was equipped with a 30m length,0.25mm I.D.,0.25?m film thickness HP-5MS(5% phenyl-methylpolysiloxane).Helium was used as the carrier gas at a constant flow rate of 1.0mL/min.The 1?l samples was injected GC/MS in split mode of 10∶1.The temperature program:160℃ for 2min,10℃/min up to 280℃ and hold for 10min.The injector,MS quadrupole rods,ion source and transfer line were kept at 250℃,150℃,230℃ and 280℃,respectively.The EI electron impact energy was 70eV.Results The extractive yield with acetic ether for blood chlormezanone was 82.1%,RSD=6.6%,implying that and acetic ether is an ideal extraction solvent.The calibration curve was y=13 852x+140 588,r=0.998 2.The detection limit was 4?g/L(SCAN m/z 30-280)and 0.1?g/L(SIM m/z 98,152,154).The RSD of precision in one day was 2.6%.The RSD of the precision between days was 4.9%.Conclusions The extraction and analysis method is suitable to the diagnosis of the acute poisoning patient of chlormezanone.